该研究旨在确定放射性药物（Ga68-PSMA-617）的生理和病理生理分布，并根据实验室、组织病理学和临床结果调查分布是否存在影响图像评估的差异。此外，我们还旨在确定区分前列腺、骨和淋巴结的生理和病理摄取的临界值。对在我们科室接受 Ga68-PSMA PET/CT 的 229 例前列腺癌患者进行回顾性分析。根据PET/CT结果、格里森评分、PSA值、接受的治疗、转移状态和其他实验室值对患者进行分组。比较各亚组患者器官、组织和病理病变的SUV值，各组间淋巴结和骨的生理摄取无显着差异。在接受雄激素剥夺治疗（ADT）的患者组中，骨转移SUV值较高，而颌下腺和肾皮质的SUV值较低（Mann-Whitney U，p = 0.043；分别为 0.004；0.01）。在接受放射治疗的患者组中，正常前列腺组织 SUV 值被确定为较高（Mann-Whitney U，p = 0.009）。血清LDH值高的患者下颌下腺、肌肉、肝脏和血池的SUV值较低。原发性前列腺病变的SUVmax截止值为6.945（敏感性89.6%，特异性98.1%）； 4.72为淋巴结转移； 4.25为骨转移。区分阴性/阳性组的血清 PSA 截止值为 1,505（敏感性 79.7%，特异性 77.3%）。 总之，PSMA-617 表现出与其他 PSMA 配体相似的生物分布。前列腺癌中主要转移的淋巴结和骨的生理摄取不受我们检查的因素的影响。需要注意的是，接受放疗的患者正常前列腺组织的摄取可能会增加，并且由于接受ADT的患者PSMA表达的变化，器官的生理/病理摄取可能会有所不同，肿瘤负荷和肾功能可能会影响生物分布。© 2024。作者。

The study aims to determine the physiological and pathophysiological distribution of the radiopharmaceutical (Ga68-PSMA-617) and investigate whether there are differences in distribution according to the laboratory, histopathological and clinical findings that can affect image evaluation. Also, we aimed to determine cut-off values to distinguish physiological and pathological uptake in prostate, bone, and lymph nodes.229 prostate cancer patients who underwent Ga68-PSMA PET/CT at our department were retrospectively analyzed. The patients were grouped according to PET/CT results, Gleason scores, PSA values, received treatments, metastatic status and other laboratory values. The SUV values of the organs, tissues, and pathological lesions of the patients in these subgroups were compared among themselves.No significant difference was detected in the physiological uptake of lymph nodes and bone between the groups. In the group with patients that received androgen deprivation therapy (ADT), the bone metastasis SUV values were found to be higher and the SUV values of the submandibular gland and renal cortex were found to be lower (Mann-Whitney U, p = 0.043; 0.004; 0.01, respectively). In the group with patients who received radiotherapy, the normal prostate tissue SUV values were determined to be higher (Mann-Whitney U, p = 0.009). The SUV values of the submandibular gland, muscle, liver, and blood pool were found to be lower in the group of patients with high serum LDH values. The cut-off SUVmax value was determined to be 6.945 (sensitivity 89.6%, specificity 98.1%) for primary prostate lesion; 4.72 for lymph node metastasis; 4.25 for bone metastasis. The serum PSA cut-off value to distinguish the negative/positive groups was found to be 1,505 (sensitivity 79.7%, specificity 77.3%).In conclusion, PSMA-617 demonstrates a similar biodistribution with other PSMA ligands. The physiological uptake of lymph nodes and bone which are mostly metastasized in prostate cancer, are not affected by the factors we examined. It should be kept in mind that the normal prostate tissue uptake may increase in patients receiving radiotherapy, and the physiological/pathological uptake of the organs may differ due to the changes in PSMA expression in patients receiving ADT, tumor burden, and kidney function may affect the biodistribution.© 2024. The Author(s).